Organization | Jingzhou Central Hospital

Jingzhou Central Hospital Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Jingzhou China (1950)

Organization Overview

First Clinical Trial

2014

NCT02202928

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Jingzhou Central Hospital

Active Ingredients

Drugs in Phase 3 Trials (1)

borneol (1 trial)

Drugs in Phase 2 Trials (7)

autologous cytokine induced killer cells (2 trials)

autologous dendritic cells loaded with autologous tumor lysate (1 trial)

bevacizumab (avastin) (1 trial)

cd19 car-t cells (3 trials)

cisplatin (platinol) (1 trial)

gemcitabine (gemzar) (1 trial)

sintilimab (1 trial)

Drugs in Other Trials (2)

propofol (diprivan) (1 trial)

remimazolam (Byfavo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colorectal Neoplasms (Phase 2)

Digestive System Diseases (Phase 2)

Digestive System Neoplasms (Phase 2)

Gastrointestinal Diseases (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Intestinal Neoplasms (Phase 2)

Neoplasms (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Stomach Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 9
# of Trial APIs: 10